PAVmed (NASDAQ:PAVM) Share Price Crosses Below 50-Day Moving Average of $2.19

PAVmed Inc. (NASDAQ:PAVM) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.19 and traded as low as $1.81. PAVmed shares last traded at $1.97, with a volume of 30,577 shares trading hands.

PAVmed Trading Up 5.3 %

The business has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $3.13. The stock has a market cap of $18.06 million, a price-to-earnings ratio of -0.21 and a beta of 0.85.

Institutional Investors Weigh In On PAVmed

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in PAVmed by 5.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 195,167 shares of the company’s stock valued at $258,000 after purchasing an additional 10,458 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of PAVmed in the 1st quarter worth approximately $196,000. Wells Fargo & Company MN grew its position in shares of PAVmed by 18.6% in the 4th quarter. Wells Fargo & Company MN now owns 366,570 shares of the company’s stock worth $176,000 after acquiring an additional 57,533 shares in the last quarter. Lido Advisors LLC grew its position in shares of PAVmed by 400.0% in the 1st quarter. Lido Advisors LLC now owns 50,000 shares of the company’s stock worth $66,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of PAVmed by 108.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 72,609 shares of the company’s stock worth $62,000 after acquiring an additional 37,724 shares in the last quarter. Institutional investors and hedge funds own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.